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Abstract
Background: Robot-assisted laparoscopic radical prostatectomy (RALP) has become
widely used without high-grade evidence of superiority regarding long-term clinical
outcomes comparedwith open retropubic radical prostatectomy (RRP), the gold standard.
Objective: To compare patient-reported urinary incontinence and erectile dysfunction
12 mo after RALP or RRP.
Design, setting, and participants: This was a prospective, controlled, nonrandomised
trial of patients undergoing prostatectomy in 14 centres using RALP or RRP. Clinical-
record forms and validated patient questionnaires at baseline and 12 mo after surgery
were collected.
Outcome measurements and statistical analyses: Odds ratios (ORs) were calculated
with logistic regression and adjusted for possible confounders. The primary end point
was urinary incontinence (change of pad less than once in 24 h vs one time or more per
24 h) at 12 mo. Secondary end points were erectile dysfunction at 12 mo and positive
surgical margins.
Results and limitations: Of 2625 eligible men, 2431 (93%) could be evaluated for the
primary end point. At 12 mo after RALP, 366 men (21.3%) were incontinent, as were 144
(20.2%) after RRP. The adjusted OR was 1.08 (95% conﬁdence interval [CI], 0.87–1.34).
Erectile dysfunction was observed in 1200 men (70.4%) 12 mo after RALP and 531
(74.7%) after RRP. The adjusted OR was 0.81 (95% CI, 0.66–0.98). The frequency of
positive surgical margins did not differ signiﬁcantly between groups: 21.8% in the RALP
group and 20.9% in the RRP group (adjusted OR: 1.09; 95% CI, 0.87–1.35). The non-
randomised design is a limitation.
y The LAPPRO Steering Committee members are listed in Appendix 1.
* Corresponding author. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy,
University of Gothenburg, Sahlgrenska University Hospital, SE 416 85 Go¨teborg, Sweden.
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1. Introduction
In prostate cancer (PCa) treatment, the aim of retaining
urinary continence and full sexual health after treatment is
universal. Surgeons who perform radical prostatectomy (RP)
continuously accumulate experience and develop their
technical skills, resulting in improved urinary continence
and sexual health [1]. The traditional surgical approach is
opensurgery (retropubicRP [RRP]), onwhich theevidence for
RP as a cure for PCa rests [2]. Over the past 20 yr, laparoscopic
methods have been developed; however, reviews of clinical
and oncologic outcomes do not favour laparoscopy over RRP
[3,4]. Robot-assisted laparoscopic prostatectomy (RALP) was
introducedwith the aimof improving surgical outcomes, but
controlledor randomisedstudieson the long-termeffects are
few and present knowledge of effectiveness is based mainly
on case series or registry data [4–7].
During RALP, the surgeon has a three-dimensional view
of the operating field that shouldmimic open surgery better
than the two-dimensional view with the laparoscopic
technique. Performing RRP, the surgeon is guided by the
use of external loupes and a headlight; RALP incorporates
high-level resolution and enlarged images as well as
excellent lighting conditions [8]. In open surgery, the
surgeon uses digital palpation of the prostatic contours to
identify anatomic landmarks and gain haptic feedback from
the tissues, including a direct sense of traction force. These
approaches cannot be used in the robot-assisted technique.
Consequently, each technique is likely to have technical
pros and cons that may reflect on postoperative urinary and
sexual function.
We initiated a prospective, controlled, nonrandomised
trial in which the interventionwas RALP and the control was
RRP. The short-term results have been reported with longer
operating time, less blood loss during surgery, and shorter
length of hospital stay for RALP compared with RRP [9].
In this analysis, the aim was to determine patient-
reported urinary incontinence and erectile dysfunction
12 mo after RP performed by RRP or RALP.
2. Patients and methods
Details of patients and methods are shown in Supplement 1.
The Laparoscopic Prostatectomy Robot Open (LAPPRO) study had an
open, prospective, controlled, nonrandomised study design and included
patients from seven centres performing RALP, at which only 4% of the
included radical prostatectomies were RRPs, and seven different centres
performing RRP, at which RALP was not performed. To minimise
differences between groups, we collected information on risk factors and
made adjustments during analysis of the data. The design and data
collection have been described previously [9,10].
The LAPPRO trial was registeredwith the ISRCTN (ISRCTN06393679).
The regional ethics review board in Gothenburg, Sweden, approved the
study (approval 277-07).
All men diagnosed with PCa and scheduled for RP at 14 participating
centres were screened for possible inclusion in the study (Fig. 1). For
this analysis, patients had to meet the following inclusion criteria:
age<75 yr; ability to read andwrite Swedish; written informed consent;
tumour stage cT1, cT2, or cT3; no signs of distant metastases; and
prostate-speciﬁc antigen (PSA) concentration <20 ng/ml. To decrease
the inﬂuence of the initial learning period in this analysis, we included
only patients operated on by surgeons with experience of 100
procedures [11,12].
The primary end point was urinary incontinence 12mo after surgery,
as reported by the patients, in an attempt to decrease bias owing to
patient–surgeon relationships [13–15]. The time point is appropriate, as
little change was seen in continence later than 12 mo after surgery
[16,17]. The questionnaire used the same clinometric approaches as
those used previously [18–22]. The questionnaire included 39 questions
about urinary function, most of which have been used before
[14,23,24]. For the primary end point, we asked, ‘‘How many times do
you change pad, diaper, or other sanitary protection during a typical
24 hours?’’ Answer categories are given in Table 1. For the secondary end
point of self-reported erectile dysfunction, we used a Swedish
translation of question 3 from the International Index of Erectile
Function [25] score: ‘‘When you had erections with sexual stimulation,
how often was your erection hard enough for penetration during the last
3 months?’’ Answer categories are given in Table 2. The questionnaire
included further questions about urinary leakage (Table 1) [26] and
erectile dysfunction (Table 2). The analyses did not include adjustment
for treatment of erectile dysfunction.
The secondary end point of positive surgical margin, included in the
analysis as a surrogate variable for oncologic safety, was based on the
clinical record form alternatives of no information, negative, focal,
extensive, or other. In the analysis, we combined focal and extensive into
positive surgical margin status.
2.1. Statistical analysis
After interim analysis, group sizes were set at 700 patients in the RRP
group and 1400 in the RALP group to yield 80% power to detect an
absolute difference of 5%, based on a signiﬁcance level of 0.05 and a two-
sided test, under the assumption that urinary incontinence after RRP
would be 10–18%.
The statistical analysis plan deﬁned effect measures, possible
confounders and mediators, and certain sensitivity analyses. The
primary end point was dichotomised between change of pads less than
once per 24 h and one time or more per 24 h.
The choice of possible confounders to urinary continence was based
on 17 probable risk factors, and the main effect measure of the primary
Conclusions: In a Swedish setting, RALP for prostate cancer was modestly beneﬁcial in
preserving erectile function compared with RRP, without a statistically signiﬁcant
difference regarding urinary incontinence or surgical margins.
Patient summary: We compared patient-reported urinary incontinence after prostatec-
tomy with two types of surgical technique. There was no statistically signiﬁcant
improvement in the rate of urinary leakage, but there was a small improvement
regarding erectile function after robot-assisted operation.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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end point was based on 50 imputed data sets. The imputation was
performed in R, with use of theMultiple Imputations by Chained Equations
function [27]. With the primary end point as the outcome, we used
successive model formation (forward selection) with the level of
signiﬁcance set at 0.20 to obtain a ﬁnal model of predictors; any
variable included in >25 of the 50 imputed models was taken to be a
possible confounder (Supplement 1; Supplementary Table 1a). This
procedure was repeated for the secondary end point, based on
19 probable risk factors for erectile dysfunction (Supplement 1;
Supplementary Table 1b).
As measures of effect, we report unadjusted relative risk ratios (RRs),
calculated with log-binomial regression models and, due to lack
convergence of log-binomial models, unadjusted and adjusted odds
ratios (ORs) calculated with logistic regression models (Supplementary
Table 2–4). The effect of possible mediators on the primary end point
was analysed in a stepwise fashion adjusting for four factors describing
preoperative tumour stage, each considered one at a time and then all
four together: PSA concentration, Gleason score at biopsy, clinical
tumour stage, length of cancer in biopsy sample, and neurovascular
bundle preservation during the operation (Table 1b and 2). We
calculated 95% conﬁdence intervals (CIs) for all models. The adjusted
ORs were based on a pooled estimate from the 50 imputed data sets. We
made the calculations for measures of effect in SAS v.9.3 for Windows
(SAS Institute Inc., Cary, NC, USA).
Eight possible confounders were deﬁned and tested in a univariate
analysis for the secondary end point reﬂecting oncologic safety: cancer
cells in the surgical margin of specimens reported at pathology
examination (Supplementary Table 1c).
3. Results
3.1. Demography
Of 2625 eligible men, 2431 (93%) could be assessed for the
primary end point (Fig. 1). Return of the clinical record
forms varied from 97% to 99%, and response rate for
questionnaires ranged from 89% to 99%.
Preoperative tumour characteristics did not differ
significantly between the groups, except that clinical stage
T2 tumours were more frequent in the RALP group than in
the RRP group, and the total number of biopsies was higher
in the RRP group than in the RALP group (Table 3). Patients
undergoing RALP had higher educational levels, higher
American Society of Anesthesiologists classification scores,
and lower body mass index values than patients in the RRP
group (Table 3). The skin-to-skin operative time was
significantly longer for RALP, as was total time in the
operating room. Significantly more patients underwent
neurovascular bundle preservation during RALP, and
significantly more lymph node dissections were made
during RRP. Perioperative bleeding was less and the length
of hospital stay was shorter in the RALP group (Table 3).
There was no significant difference between groups
regarding frequencies of treatment with radiation or
endocrine substances at 12 mo after surgery.
[(Fig._1)TD$FIG]
Patients (n = 4003) 
No informed consent (n = 21) 
Robot-assisted laparoscopic radical 
prostatectomy (n = 1847) 
Evaluable (n = 2625)
Reported to the study register 
Start date: 1 September 2008 
End date: 7 November 2011 
Excluded (n = 122) 
Aged >75 yr  
PSA level ≥20 ng/ml 
Tumour stage >T3 
Metastatic disease 
Withdrawn consent; not understanding 
Swedish; physical, psychosocial, and 
practical reasons (n = 281) 
Open radical prostatectomy (n = 778) 
Surgeon performed <100 operations  
(n = 980) 
No cancer in surgical specimen (n = 2) 
No operation performed (n = 26) 
Fig. 1 – Flow diagram. Numbers may not sum properly, as the same participant may have fulfilled more than one exclusion criterion.
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3.2. Urinary incontinence
The following variables occurred in 34 of the 50 imputed
models and were selected as possible confounders: age,
diabetes mellitus, mental disorder, history of abdominal
surgery, prostate weight, pulmonary disease, and employ-
ment status.
When adjusted for possible confounders, no statistically
significant difference in ORs was found between groups for
any definition of urinary incontinence, as the 95% CIs for all
ORs covered unity (Table 1). The adjusted OR of urinary
incontinence as defined for the primary analysis (at least
one pad changed per 24 h) at 12 mo was 1.21 (95% CI, 0.96–
1.54), and the 95% CIs for the ORs comparing any frequency
of changing pads covered unity (Table 1a). When the
additional questions concerning details of urinary leakage
and discomfort were taken into account, the proportions of
patients classified as having urinary incontinence ranged
from 20% to 56% after RRP and from 21% to 57% after RALP,
with the higher frequencies found when we assessed
urinary incontinence by a combination of not pad-free and
not leakage-free (Table 1b).
A sensitivity analysis of influence of including centre,
calculating unadjusted RRs withdrawing one centre at a
time, did not result in any significant difference among
centres. The effects of preoperative tumour characteristics
on urinary incontinence (Table 1b) resulted in ORs ranging
from 1.32 to 0.95, and all 95% CI values covered 1.0,
regardless of the definition of urinary incontinence used,
indicating that this contrast was not significant. The
Table 1a – Urinary incontinence at 12 mo for comparisons of open and robot-assisted laparoscopic surgery, as reported by patients
<1 pad * 1 pad * 2–3 pads * 4–5 pads * 6 pads *
Robot-assisted surgery, % 175 (10) 230 (13) 103 (6.0) 19 (1.1) 14 (0.8)
Open surgery, % 96 (13) 85 (12) 40 (5.6) 12 (1.7) 7 (1.0)
Deﬁnition of outcome >0 1 2 4 6
<1 pad * 1 pad * 2 pads * 4 pads * 6 pads *
Adjusted A OR ** (95% CI) 1.00
(0.82–1.23)
1.21
(0.96–1.54)
1.05
(0.74–1.49)
0.91
(0.48–1.71)
0.99
(0.37–2.65)
Adjusted B OR y (95% CI) 1.01
(0.81–1.26)
1.24
(0.96–1.60)
1.17
(0.79–1.74)
1.13
(0.54–2.38)
0.98
(0.33–2.90)
CI = conﬁdence interval; OR = odds ratio.
* To determine use of protective measure against urinary leakage (eg, pads), patients were asked, ‘‘How many times do you change pad, diaper or other
sanitary protection during a typical 24 hours?’’ The following responses were available: ‘‘Not applicable, I do not use pad, diaper or a sanitary protection,’’
‘‘Less than once per 24 hours,’’ ‘‘About once per 24 hours,’’ ‘‘About two to three times per 24 hours,’’ ‘‘About four to ﬁve times per 24 hours,’’ or ‘‘About six
times or more per 24 hours’’ [24].
** Adjusted A: adjusted for age at surgery, inguinal hernia, abdominal surgery, diabetes, pulmonary disease, mental disorder, prostate weight.
y Adjusted B: adjusted for same as A plus all four preoperative tumour factors.
Table 1b – Urinary incontinence measured by various definitions as reported by patients 12 mo after surgery
Deﬁnition of urinary incontinence Open surgery,
n (%)
Robot-assisted
surgery, n (%)
Adjusted A,
OR (95% CI) *
Adjusted B,
OR (95% CI) y
Adjusted C,
OR (95% CI) z
Change of pad § at least once per 24 h
(primary end point)
144 (20) 366 (21) 1.21
(0.96–1.54)
1.24
(0.96–1.60)
1.31
(1.01–1.70)
Not pad free § and not leakage free 399 (56) 978 (57) 1.14
(0.94–1.37)
1.18
(0.96–1.44)
1.20
(0.98–1.47)
Urinary leakage daytime 252 (35) 606 (35) 1.13
(0.93–1.38)
1.16
(0.94–1.44)
1.19
(0.96–1.48)
Any urinary leakage daytime 367 (51) 902 (52) 1.14
(0.95–1.38)
1.16
(0.95–1.42)
1.19
(0.97–1.45)
Do you have urinary leakage? 117 (17) 310 (18) 1.28
(0.99–1.65)
1.32
(1.00–1.73)
1.38
(1.05–1.83)
Urinary discomfort 261 (37) 592 (35) 0.96
(0.79–1.17)
0.95
(0.77–1.17)
0.98
(0.79–1.21)
CI = conﬁdence interval; OR = odds ratio.
Information on unadjusted risk and ORs is available in Supplementary Table 2.
* Adjusted A: adjusted for age at surgery, inguinal hernia, abdominal surgery, diabetes, pulmonary disease, mental disorder, prostate weight.
y Adjusted B: adjusted for same as A plus all four preoperative tumour factors.
z Adjusted C: adjusted for same as A plus B plus degree of neurovascular bundle preservation.
§ To determine use of protective measure against urinary leakage (eg, pads), patients were asked, ‘‘How many times do you change pad, diaper or other
sanitary protection during a typical 24 hours?’’ The following responses were available: ‘‘Not applicable, I do not use pad, diaper or a sanitary protection,’’
‘‘Less than once per 24 hours,’’ ‘‘About once per 24 hours,’’ ‘‘About two to three times per 24 hours,’’ ‘‘About four to ﬁve times per 24 hours,’’ or ‘‘About six
times or more per 24 hours’’ [24].
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Table 2 – Erectile dysfunction compared between open and robot-assisted laparoscopic surgery using various definitions and as reported by
patients 12 mo after surgery
Deﬁnition of erectile dysfunction Open surgery,
n (%)
Robot-assisted
surgery, n (%)
Adjusted A,
OR (95% CI) **
Adjusted B,
OR (95% CI) y
Adjusted C,
OR (95% CI) z
IIEF score § 531 (75) 1200 (70) 0.80
(0.64–1.00)
0.79
(0.63–1.00)
0.73 (0.58–0.93)
IIEF-5 score # at 12 mo 16 570 (81) 1311 (78) 0.86
(0.68–1.09)
0.75
(0.58–0.96)
0.75 (0.58–0.97)
IIEF-5 score # at 12 mo 21 654 (93) 1508 (90) 0.71
(0.50–0.99)
0.61
(0.42–0.88)
0.61 (0.42–0.88)
Penile stiffness less than half of the time 574 (81) 1323 (77) 0.81
(0.64–1.03)
0.75
(0.59–0.96)
0.75 (0.58–0.97)
No spontaneous morning erection 664 (93) 1522 (89) 0.59
(0.42–0.82)
0.52
(0.36–0.76)
0.50 (0.35–0.74)
Erectile dysfunction, combined variable + 561 (79) 1282 (75) 0.80
(0.64–1.00)
0.74
(0.59–0.95)
0.75 (0.58–0.96)
CI = conﬁdence interval; IIEF = International Index of Erectile Function; OR = odds ratio.
Information on unadjusted risk and ORs is available in Supplementary Table 3.
** Adjusted A: adjusted for age at surgery, educational level, smoking, employment, cardiovascular disease.
y Adjusted B: adjusted for same as A plus all four preoperative tumour characteristic variables.
z Adjusted C: adjusted for same as A plus B plus degree of neurovascular bundle preservation.
§ IIEF Questionnaire, question 3: ‘‘When you had erections with sexual stimulation, how often was your erection hard enough for penetration during the last
3 months?’’ with cutoff between response 2 and 3. The following responses were available: ‘‘No sexual activity’’ (0); ‘‘Almost never or never’’ (1); ‘‘A few
times (much less than half the time)’’ (2); ‘‘Sometimes (about half the time)’’ (3); ‘‘Most times (much more than half the time)’’ (4); and ‘‘Almost always or
always’’ (5).
# IIEF Questionnaire modiﬁed version with ﬁve questions, six answer categories, 0–5 points per question; score 16 = erectile dysfunction; score 21 = some
erectile function.
+ Erectile dysfunction implies a lack of stiffness at sexual activity or morning erection.
Table 3 – Baseline patient, perioperative, and 12-mo follow-up characteristics
Characteristic Open retropubic
radical prostatectomy *
(n = 778)
Robot-assisted laparoscopic
radical prostatectomy *
(n = 1847)
p value
Preoperative characteristics
Age at surgery, yr
Median (IQR) 63 (59–67) 63 (58–66) 0.03
Preoperative PSA level, ng/ml
Median (IQR) 6.2 (4.5–9.0) 6.1 (4.5–8.9) 0.73
Not stated 4 5
Preoperative clinical tumour stage
cT1 494 (64) 1099 (60) 0.006
cT2 218 (28) 652 (35)
cT3 27 (3.5) 57 (3.1)
Not stated 39 (5.0) 39 (2.1)
Preoperative biopsy Gleason score
7 716 (92) 1732 (94) 0.7
8 45 (5.8) 102 (5.5)
Not stated 17 (2.2) 13 (0.7)
Total length of cancer in prostate biopsy, mm
Median (IQR) 7.0 (3.2–15) 7.5 (4.0–16) 0.07
Not stated 74 71
Cores taken at prostate biopsy, no.
Median (IQR) 10 (10–11) 10 (9–10) <0.001
Not stated 36 73
IPSS score **
Mild 0–7 363 (52) 908 (56) 0.3
Moderate 8–19 265 (38) 597 (37)
Severe 20–35 49 (7.1) 95 (5.8)
Not stated 17 (2.4) 30 (1.8)
Preoperatively continent y
<1 675 (97) 1606 (98) 0.2
1 12 (1.7) 17 (1.0)
Not stated 7 (1.0) 7 (0.4)
Preoperatively potent
Yes 489 (71) 1166 (72) 0.8
No 182 (26) 421 (26)
Not stated 23 (3.3) 43 (2.6)
Residence
Urban 566 (82) 1396 (86) 0.05
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Table 3 (Continued )
Characteristic Open retropubic
radical prostatectomy *
(n = 778)
Robot-assisted laparoscopic
radical prostatectomy *
(n = 1847)
p value
Rural 118 (17) 216 (13)
Abroad 5 (0.7) 8 (0.5)
Not stated 5 (0.7) 10 (0.6)
Level of education
University/college 246 (36) 691 (42) 0.009
Technical training school 80 (12) 184 (11)
High school 208 (30) 462 (28)
Elementary school 143 (21) 254 (16)
Other 14 (2.0) 30 (1.8)
Not stated 3 (0.4) 9 (0.6)
Marital status
Partner 636 (92) 1467 (90) 0.2
Single 54 (7.8) 153 (9.4)
Not stated 4 (0.6) 10 (0.6)
Preoperative BMI, kg/m2
Median (IQR) 26.2 (24.5–28.1) 25.9 (24.1–28.0) 0.03
Not stated 12 32
Preoperative ASA score z
1 508 (67) 1113 (60) 0.005
2 218 (29) 646 (35)
3 15 (2.0) 43 (2.3)
Not stated 22 (2.9) 42 (2.3)
Perioperative characteristics
Skin-to-skin operating time, min
Median (IQR) 89 (74–125) 168 (144–201) <0.001
Not stated 32 310
Total time in operating room, min
Median (IQR) 126 (102–186) 236 (210–270) <0.001
Not stated 158 321
Neurovascular bundle preservation, no. (%)
No neurovascular dissection 246 (32) 287 (16) <0.001
Uni- or bilateral partial dissection 63 (8.3) 244 (13)
Unilateral inter- or intrafascial dissection 104 (14) 339 (18)
Bilateral, partial dissection on one side 63 (8.3) 368 (20)
Bilateral, interfascial dissection on both sides 182 (24) 388 (21)
One side interfascial, one intrafascial dissection 18 (2.4) 122 (0.7)
Intrafascial dissection on both sides 84 (11) 93 (5.0)
Not stated 1 (0.1) 2 (0.1)
Lymph node dissection
No 553 (73) 1604 (87) <0.001
Yes 206 (27) 235 (13)
Not stated 2 (0.3) 4 (0.2)
Perioperative bleeding, ml
Median (IQR) 550 (350–800) 100 (50–200) <0.001
Not stated 12 127
Pathology tumour stage
pT2 562 (74) 1287 (71) 0.2
pT3 190 (25) 511 (28)
pT4 3 (0.4) 10 (0.6)
pTX 0 (0.0) 7 (0.4)
Not stated 7 (0.9) 6 (0.3)
Surgical margin status
Negative 585 (77) 1399 (77) 0.15
Positive 154 (20) 399 (22)
Not stated 23 (3.0) 23 (1.3)
Prostatectomy specimen Gleason score
7 643 (84) 1657 (91) 0.005
8 30 (3.9) 138 (7.6)
Not stated 89 (12) 26 (1.4)
Length of hospital stay, d
Median (IQR) 4 (3–5) 3 (2–4) <0.001
Not stated 3 1
ASA = American Society of Anesthesiologists; BMI = body mass index; IPSS = International Prostate Symptom Score; IQR = interquartile range; PSA = prostate-
speciﬁc antigen.
* Because of rounding, percentages may not total 100.
** Seven questions with six answers each, 0–5 points per question. A high score indicates better erectile function.
y Use of protective measure (eg, pads), described as number of changes per 24 h.
z 1 = normal healthy patient, 2 = mild systemic disease, 3 = severe systemic disease.
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definition used for the primary end point resulted in an OR
of 1.31 (95% CI, 1.01–1.70) after adjustment for background
factors, tumour characteristics, and neurovascular preser-
vation (Table 1b). The ORs for other definitions of
incontinence all had 95% CIs covering 1.0 after adjustment,
indicating that there were no statistically significant
differences between the two techniques.
3.3. Erectile dysfunction
The following confounding variables (occurring in 42 of
50 imputed models) were selected as possible: age at
surgery, educational level, smoking status, employment
status 12 mo after surgery, and history of cardiovascular
disease. After adjustment, the OR for any erectile dysfunc-
tion was 0.80 (95% CI, 0.64–1.00) (Table 2). Classification of
erectile dysfunction by different definitions did not
substantially affect the ORs (Table 2). When adjustments
were made for the preoperative clinical tumour character-
istics, OR was 0.74 (95% CI, 0.59–0.95); the neurovascular
preservation OR was 0.75 (95% CI, 0.58–0.96) (Table 2); and
adjusting for lymph node dissection resulted in an OR of
0.78 (95% CI, 0.61–1.00).
3.4. Positive surgical margin
Of the possible confounders, only prostate weight was
carried through to the final analysis. The frequencies of
positive surgical margin were 22% and 21% for RALP and
RRP, respectively (Table 4), and the unadjusted and adjusted
RRs and ORs all had 95% CIs covering 1.0.
4. Discussion
This large, prospective, controlled, nonrandomised trial to
evaluate outcomes of RALP in comparison with RRP showed
no statistically significant difference regarding the primary
end point: patient-reported urinary incontinence 12 mo
after surgery. However, for erectile dysfunction 12 mo after
the operation, fewer patients were affected after RALP than
after RRP. The surgical approach made no difference in the
rate of positive surgical margins, a surrogate marker for
oncologic outcome.
Hu and coworkers performed a registry-based study of
reimbursement claims for urinary incontinence after
minimally invasive RP, includingRALP [7]. Their propensity
model–adjusted figures were 15.9 per 100 person-
years for minimally invasive surgery and 12.2 for RRP,
which resulted in a ratio of reimbursement claims of
1.30 (95% CI, 1.05–1.61). In contrast, we based our analyses
of urinary incontinence on patients’ self-reported experi-
ences of urinary incontinence. All procedures in our
study were performed by surgeons who had performed
100 procedures, whereas Hu and coworkers did not take
surgeon experience into account. We found no statistically
significant difference regarding incontinence when com-
paring RALP and RRP. A recent report on learning curve
found a surgeon ‘‘break-even point’’ regarding urinary
continence of 182 cases [12].
Several reports have been published on single-institu-
tion case series [28–30], in which selection-induced
problems leading to confounding by indication might
compromise the interpretation when comparing two
simultaneously performed techniques because of surgeon
and/or patient preferences. Patient selection by the surgeon
may imply that more complex cases with higher risk of
untoward results would not be included, resulting in better
outcomes, whereas a selection of treatmentmodality by the
patient may be due to an assumption of results of the
chosen procedure, which could influence the patients’
perception of outcomes postoperatively. Ahlering et al
found no difference in urinary incontinence at 3 mo
postoperatively [28], whereas Ficarra et al reported a
significantly better continence at 12 mo after RALP
compared with RRP [29]. With the design of our trial,
unaccounted-for problems induced by selection should be
small, and our result—finding no statistically significant
difference in urinary incontinence between the two
techniques—should accurately reflect practice in Sweden
at the time. When Barry et al assessed data from a national
registry asking patients about urinary incontinence after
RALP or RRP, they found no statistically significant
difference in outcomes between techniques [30].
We suggest that in the future, the appropriate definition
of urinary incontinence from the patient’s perspective
should be not pad-free and not leakage free, as indicated
when taking the patient’s bother into account [26].
In our study, RALP resulted in a statistically significantly
higher proportion of men (30%) with erectile function
12mo after surgery than did RRP (25%), but the majority of
the men in the two groups experienced negative effects on
sexual health. Hu and coworkers reported 26.8 reimburse-
ment claims per 100 person-years for erectile dysfunction
afterminimally invasive surgery and 19.2 for open surgery,
which gives an OR of 1.40 (95% CI, 1.14–1.72) [7]. Their
definition of erectile dysfunction is quite different from
that used in our study, which is probably an important
reflection of the differences in frequencies; themethod and
Table 4 – Comparison of open surgery and robot-assisted laparoscopic surgery concerning positive surgical margins
Open surgery, n/N (%) Robot-assisted surgery, n/N (%) Adjusted RR * (95% CI) Adjusted OR (95% CI)
PSMs ** 156/748 (21) 395/1812 (22) 1.06
(0.90–1.26)
1.09
(0.87–1.35)
CI = conﬁdence interval; OR = odds ratio; PSM = positive surgical margin; RR = relative risk.
* Relative risk: percentage with outcome in the continent group divided by percentage with outcome in the incontinent group for each possible cutoff.
** Deﬁned as a pathology report of cancer cells present in the surgical margin.
E U RO P E AN URO LOG Y 6 8 ( 2 0 1 5 ) 2 1 6 – 2 2 5222
definition we used should reflect the reality more closely.
The high level of erectile dysfunction reported in our study
is most probably explained by the use of validated
questionnaires sent to a third party, the high answering
rates, and the population basis for the cohort. In compari-
son to a recent report from a highly specialised tertiary
referral centre [17], the rates of erectile dysfunction in our
trial are higher, but there are noteworthy differences in
answering rates (at most, 62% vs >90% in our trial), apart
from the unknown effect of referral as such. A meta-
analysis of six comparative studies reported better return
to sexual health after RALP than after RRP at 12mo, with an
OR of 2.84 (95% CI, 1.46–5.43) [31]. We found a small but
statistically significant difference in favour of RALP (70%)
versus RRP (75%), and that difference persisted after using
various definitions of erectile dysfunction and after
adjustments. However, the absolute difference of 5% was
modest. The health-economic analysis, which is part of our
trial protocol and still to be performed, will be of
considerable interest.
For valid comparisons among studies, the definitions of
urinary incontinence and erectile dysfunction, ideally,
should be identical. In our study, we were able to use a
number of definitions by asking several questions and
found consistent results for comparisons of the two
techniques, and we conclude that the results are robust.
Self-reported data can vary in validity depending on
whether questionnaires are returned to a neutral third party
instead of the centre responsible for the surgery [13,14]. Sig-
nificant differences regarding urinary incontinence com-
paring interviews in the clinical setting with questionnaires
have been reported [15]. We chose questionnaires and
central administration to ensure that contacting, sending,
and reminding were uniform and to avoid patient
dependency.
The strengths of our study include the prospective
controlled design; the sample size; the short inclusion
period; the high participation and response rates; the
experience of the surgeons; the collection of information
before, during, and after surgery; and the use of validated
measures. A concern before start of the study was that the
lack of randomisation could lead to an imbalance between
groups for important risk factors for urinary incontinence.
This imbalance was counteracted by collection of informa-
tion about possible risk factors and use of this information
for adjustments during analyses. Themodest changes in RRs
and ORs after adjustments indicate that the residual
confounding effects of lack of randomisation (selection-
induced problems) are small, if any, with regard to the
assessment of the primary end point. The case volumes of
the surgeons and the centres might influence the rates of
urinary incontinence and erectile dysfunction at 12mo. The
effect of surgeon experience on outcome in terms of
recurrence has been described by Vickers et al [32], and this
variable as well as functional outcomes are of interest from
a planning perspective in national health care systems and
for individual patients. An analysis of this aspect within the
framework of this trial, including initial experience, is
planned. In this analysis, our aim was to study the mean
competence at the time in Sweden for the respective
techniques at the experience level of 100 operations.
5. Conclusions
Earlier suggestions of improved erectile function, although
modest, after RALP were substantiated, whereas improve-
ment of urinary continence was not.
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